Sustainability Meeting 27 November 2025 CHUGAI PHARMACEUTICAL CO., LTD. Important Reminder This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the "Company"). These statements reflect the Company's current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company's businesses. Information regarding pharmaceuticals (including products un ...

多维宣传培训 夯实安全意识基础 鲁西新区坚持"宣传+培训"双轮驱动，全面提升公众与行业人员安全素养。在集中宣传方面，借助3.15 国际消费者权益日、药品安全宣传周等重要节点，通过咨询台设置、假冒伪劣药品展示、知识问答、免 费义诊等形式，向公众普及药品法律法规与安全用药知识。今年以来累计开展集中便民宣传4场次、药 品安全知识问答5场次、免费义诊5场次，发放宣传资料7000余份，有效提升了群众对日常用药的认知水 平。 齐鲁晚报·齐鲁壹点 李可 11月25日，菏泽鲁西新区召开药品安全工作新闻发布会，会议通报了鲁西新区药品安全监管工作成效、 产业发展成果，并就社会关注的热点问题回应媒体关切。 监管产业同频 驱动生物医药高质量发展 生物医药产业是鲁西新区主导产业之一，先后入选山东省先进制造业集群、省级"产业大脑"建设试点。 鲁西新区综合行政执法局在做好药品监管工作的同时，助力产业加速，助推生物医药高质量发展。目 前，步长稳心、丹红系列扩产扩能、知和大药厂、简道制药等一批重点项目全面建成，合泽药业、博瀚 制药等一批重点项目即将投产。今年以来，新签约植物空心胶囊无人化生产、百诚年产20亿片口服固体 制剂等过亿元项目11个， ...

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 27 NOVEMBER 2025 at 9.00 EET 71,498 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 71,498 A shares have been converted into 71,498 B shares. The conversion has been entered into the Trade Register on 27 November 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consi ...

One opportunity involves pharmacy benefit managers, who are middle-men between chemists and drugmakers. This is where reform is most likely to happen https://t.co/E53DGDm3nl ...

Key TakeawaysGold surged to $4,165 an ounce, driven by strong market expectations of a December US interest-rate cut, supported by dovish Federal Reserve signals and the emergence of Kevin Hassett as a top contender for Fed Chair.Johnson & Johnson (JNJ) reached a monumental $500 billion market value, extending an unprecedented 13-day winning streak fueled by investor confidence in its new drug pipeline and recent acquisitions.New Zealand's business confidence saw a significant jump in November, with the ANZ ...

Core Viewpoint - The potential strong data from Amgen's drug Maritide could exert pressure on Eli Lilly's shares, particularly due to concerns about side effects and market competition [1][3]. Company Analysis - Eli Lilly is expected to face significant competition in the obesity drug market, with three drugs already on the market and four in advanced clinical studies by the time Maritide is projected to receive FDA approval in 2028 or 2029 [3]. - The valuation of Eli Lilly is currently high, trading at approximately 35 times next year's earnings estimates, which raises concerns about its ability to move significantly higher in the short term [7][6]. - The company has seen a substantial increase in stock price, but there is a risk that favorable data for Maritide could lead investors to take profits from Eli Lilly [6]. Industry Insights - The obesity drug market is projected to grow from $20 billion in the US this year to $150 billion by 2030, indicating a transformative opportunity for companies involved in this drug class [9]. - The current drug category, including incretins and amylins, is noted for its potential to prevent morbidity and mortality associated with common chronic conditions, making it a significant area of focus for pharmaceutical companies [10]. - The Institute for Clinical Economic Research highlighted that certain drugs, like Zepbound, not only improve quality of life but also provide cost savings to the healthcare system, emphasizing the economic benefits of this drug category [10].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 8, 2025 [3]. - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage completely [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4].

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Ironwood Pharmaceuticals ( IRWD ) stock is buoyant today, up >15%, despite the CMS announcing the list price of its drug Linzess will be slashed from 2027, from $568 per month, to $136.Edmund Ingham is a biotech co ...

-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. for patent infringement rel ...

Eli Lilly and Company ( LLY ) became the first pharmaceutical company in history to reach a valuation of $1 trillion , and virtually the entire story is based on the boom in GLP-1 drugs for obesityHi, I'm Martin, I focus on maintaining a delta neutral portfolio. I want to be long/short at the same time and benefit from market volatility. I specialize in using options through which I enter and exit trades. I look for market opportunities primarily in small companies, and my search takes me into the waters of ...